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Fibroblast growth factor 23 (FGF23) is a bone-derived hormone regulating phosphate and vitamin D metabolism.
FGF23 works by binding to Klotho-FGF receptor (FGFR) complex. FGF23 reduces serum phosphate level by
suppressing the expression of type 2a and 2c sodium-phosphate cotransporters in the renal proximal tubules. In
addition, FGF23 suppresses intestinal phosphate absorption by reducing 1,25-dihydroxyvitamin D (1,25(OH)2D) level.
FGF23 also inhibits the production and secretion of parathyroid hormone. FGF23 starts to increase in the early
phase of chronic kidney disease (CKD) and is considered to prevent the development of hyperphosphatemia. With
the progression of CKD, the expression of Klotho decreases causing impaired actions of FGF23. It has been reported
that FGF23 level is correlated with various adverse events including cardiovascular diseases especially in patients
with CKD. It was also shown that FGF23 induces left ventricular hypertrophy by directly acting on cardiomyocytes
in a Klotho-independent way. However, there still remain several unanswered questions concerning FGF23-Klotho
axis. We hope that further studies elucidate unsolved problems and will be useful for more appropriate
management of patients with CKD.
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Kidney is essential for maintaining mineral metabolism.
Thus, deranged mineral metabolism and abnormal
serum concentrations of minerals including calcium (Ca)
and phosphate can be observed in patients with chronic
kidney disease (CKD). CKD-mineral and bone disorder
(CKD-MBD) was defined as a systemic disease including
abnormal mineral and bone metabolism, ectopic calcifi-
cation [1]. CKD-MBD is at least one of conditions that
affect morbidity and mortality of patients with CKD [2].
Therefore, it has been a big challenge to understand the
pathophysiology of CKD-MBD and to develop effective
drugs for this disorder. Serum Ca level is mainly regulated
by two calciotropic hormones, parathyroid hormone
(PTH) and 1,25-dihydroxyvitamin D (1,25(OH)2D). While
these hormones can also affect serum phosphate level, the
investigations of hypophosphatemic diseases revealed that
there are other humoral factors regulating phosphate me-
tabolism than these calciotropic hormones [3]. Fibroblast
growth factor 23 (FGF23) was identified as a humoral
phosphaturic factor responsible for autosomal dominant* Correspondence: fukumoto-tky@umin.ac.jp
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osteomalacia (TIO) [4, 5]. Since then, it was shown that
excessive actions of FGF23 cause several kinds of hypo-
phosphatemic diseases [6]. In addition, deficient actions of
FGF23 result in a hyperphosphatemic disease [7], and
FGF23 is now considered to be a hormone regulating
phosphate metabolism [8, 9]. FGF23 is produced mainly
by the bone [10, 11] and binds to Klotho-FGF receptor
(FGFR) complex [12, 13]. Serum FGF23 level is high in
patients of CKD, suggesting that FGF23 has some role in
the development of CKD-MBD [14]. Here, we briefly
summarize the significance of FGF23 in patients with
CKD and discuss some controversies concerning FGF23
especially in patients with end-stage renal disease (ESRD).The structure and function of FGF23
FGF23 is produced by the bone, especially by osteocytes
[10, 11]. FGF23 protein is produced as a peptide with
251 amino acids. After the cleavage of a signal peptide
with 24 amino acids, FGF23 protein with 227 amino
acids is secreted [4, 5]. A part of FGF23 protein is pro-
teolytically cleaved between Arg179 and Ser180 into
inactive N-terminal and C-terminal fragments before or
during the process of secretion [5] (Fig. 1). FGF23 has a
FGF homology region as other members of FGF familyThis article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The structure and post-translational modification of FGF23 protein. FGF23 protein is produced as a peptide with 251 amino acids. FGF23
with 227 amino acids is secreted after the cleavage of a signal peptide with 24 amino acids. A part of FGF23 protein is cleaved between Arg179
and Ser180 into inactive N-terminal and C-terminal fragments before or during the process of secretion. O-glycosylation of Thr178 by GalNac-T3, a
gene product of GALNT3, inhibits this cleavage and increases full-length FGF23. Phosphorylation of Ser180 inhibits O-glycosylation by GALNT3 and enhances
the processing of FGF23 protein. GalNac-T3: polypeptide N-acetylgalactosaminyltransferase 3; GALNT3: polypeptide N-acetylgalactosaminyltransferase 3
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Therefore, only full-length FGF23 with 227 amino acids is
considered to have a hormonal activity. It is suggested that
FGF23 activity is regulated not only by its production but
also by post-translational modification of FGF23 protein.
It was previously shown that O-glycosylation of Thr178 in
FGF23 protein by polypeptide N-acetylgalactosaminyl-
transferase 3 (GalNac-T3), a gene product of polypeptide
N-acetylgalactosaminyltransferase 3 (GALNT3), inhibits
this cleavage and works to increase full-length FGF23 [16]
(Fig. 1). On the other hand, phosphorylation of Ser180 in
FGF23 protein by family with sequence similarity 20,
member C (FAM20C) inhibits O-glycosylation by
GALNT3 and enhances the processing of FGF23 protein
[17] (Fig. 1).
FGF23 reduces serum phosphate level by suppressing
the expression of type 2a and 2c sodium-phosphate
cotransporters in the renal proximal tubules [8] (Fig. 2).
In addition, FGF23 reduces 1,25(OH)2D level not only
by suppressing CYP27B1 expression which produces 25-
hydroxyvitamin D-1α-hydroxylase but also by enhancing
that of CYP24A1 encoding 25-hydroxyvitamin D-24-
hydroxylase [8] (Fig. 2). Because 1,25(OH)2D is a hor-
mone that enhances intestinal phosphate absorption,
FGF23 reduces serum phosphate by inhibiting both in-
testinal phosphate absorption via reducing 1,25(OH)2D
level and proximal tubular phosphate reabsorption.
FGF23 was also shown to suppress both production and
secretion of PTH in rodents [18]. Furthermore, it was
recently reported that FGF23 regulates renal calcium
and sodium handling by modifying the expression of the
calcium channel, transient receptor potential vanilloid-5
(TRPV5), and sodium-chloride cotransporter (NCC) inrenal distal tubules [19, 20] while FGF23 did not change
urinary calcium and sodium excretion in a previous
study [5]. These results indicated that FGF23 produced
by the bone works as a systemic humoral factor and sug-
gested that there is a specific receptor for FGF23 at least
in the kidney and parathyroid glands.
FGF family members have been shown to bind to
FGFRs [15]. While the affinity of FGF23 for FGFRs is
quite low, FGF23 was shown to bind to Klotho-FGFR
complex [12, 13]. Klotho was identified as a gene whose
expression was severely reduced in genetically engi-
neered mice called Klotho [21]. Both FGF23 knockout
and Klotho mice were shown to have hyperphosphate-
mia with increased renal proximal tubular phosphate
reabsorption and high 1,25(OH)2D level [9, 12, 13, 22],
indicating that FGF23-Klotho pathway is essential for
maintaining phosphate and vitamin D metabolism. How-
ever, there still remain several unsolved questions con-
cerning the mechanisms of actions of FGF23. First,
Klotho is mainly expressed in the renal distal tubules,
parathyroid glands, and choroid plexus [21]. The initial
signal after the administration of FGF23 was detected in
the distal tubules [23]. On the other hand, the actions of
FGF23 are observed in the proximal tubules. It is pos-
sible that there is an unknown communication pathway
between the renal distal tubules and proximal tubules.
In addition, while it was reported that Klotho is also
expressed in the renal proximal tubules [24], the direct
evidence that proximal tubular Klotho mediates in vivo
actions of FGF23 is lacking. Second, it is not clear how
FGF23 can regulate the expression of several genes
including CYP24A1 and CYP27B1 and those encoding
sodium-phosphate cotransporters after binding to
Fig. 2 The activities of FGF23 in the kidney. FGF23 reduces serum phosphate level by suppressing the expression of type 2a and 2c sodium-phosphate
cotransporters in the renal proximal tubules. In addition, FGF23 decreases intestinal phosphate absorption by reducing 1,25(OH)2D level
via not only suppressing CYP27B1 which produces 25-hydroxyvitamin D-1α-hydroxylase but also enhancing CYP24A1 expression encoding
25-hydroxyvitamin D-24-hydroxylase
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FGF23 uses different signal transduction pathways for
phosphate handling and vitamin D metabolism [25].
However, it is still unclear what molecules finally medi-
ate FGF23 actions and regulate gene expression in the
target cells.
FGF23 and abnormal mineral metabolism in
patients with CKD
CKD and CKD-MBD are becoming big social problems
all over the world. CKD-MBD is manifested by abnor-
malities in bone and mineral metabolism or extra skel-
etal calcification [1]. It was revealed that serum FGF23
level starts to increase early in the progression of CKD
before the increase of serum phosphate or PTH level
[26]. This increase of FGF23 was shown to be associated
with enhanced urinary phosphate excretion [27]. In
addition, the administration of neutralizing anti-FGF23
antibodies increased serum phosphate in an animal
model of early CKD [28]. Therefore, the increase of
FGF23 in patients with early CKD seems to work to pre-
vent the development of hyperphosphatemia at least in
part by enhancing urinary phosphate excretion [28]. On
the other hand, the increase of FGF23 was also associ-
ated with the decrease of 1,25(OH)2D in patients with
CKD [27]. Furthermore, the inhibition of FGF23 activity
in the animal model of CKD increased serum 1,25(OH)2D
[28]. While the reduction of 1,25(OH)2D by increased
FGF23 is likely to reduce intestinal phosphate absorption
and contribute to maintaining serum phosphate level, it
may induce or aggravate secondary hyperparathyroidism.
However, the role of FGF23 in the development ofsecondary hyperparathyroidism is complex because
FGF23 was shown to directly inhibit production and se-
cretion of PTH [18]. With the progression of CKD, the ex-
pression of Klotho in kidneys and parathyroid glands were
shown to decrease that likely leads to impaired actions of
FGF23 [29, 30]. Together with reduced nephron mass,
frank hyperphosphatemia develops in patients with ad-
vanced CKD.
While FGF23 begins to elevate in patients with early
CKD, it is not evident what triggers this increase of
FGF23. Serum phosphate and PTH are normal when
FGF23 starts to increase although phosphate and PTH
were shown to affect FGF23 level [31, 32]. While
1,25(OH)2D was shown to increase FGF23 level [33],
1,25(OH)2D is not high in patients with early CKD. It is
proposed that the reduced Klotho in patients with CKD
has some role in the increase of FGF23 [34]. Still, it is
not clear how reduced Klotho expression in kidneys or
parathyroid glands affect FGF23 production in osteo-
cytes without changing phosphate or PTH levels. It was
also reported that the impairment of renal function
affects the processing of FGF23 protein [35]. The ratio
of C-terminal fragment of FGF23 to total FGF23 protein
was lower in patients with CKD compared to that of
healthy control. However, the mechanism of this reduced
processing of FGF23 protein is not clear, either.
FGF23 and cardiovascular diseases in patients
with CKD
It has been well known that hyperphosphatemia is a risk
factor for ectopic calcification, cardiovascular diseases,
and high mortality [36]. Wolf et al. reported that serum
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tively correlated with mortality in a subsequent year
[37]. The most important finding of this report was that
the relationship between FGF23 level and mortality
remained to be significant even after adjusting by serum
phosphate level or other confounding factors. Since
then, many epidemiological studies investigated the rela-
tionship between FGF23 and various adverse events
especially in patients with CKD. High serum FGF23 level
was shown to be associated with left ventricular hyper-
trophy (LVH), heart failure, atherosclerosis, stroke, and
various cardiovascular events [38]. However, these asso-
ciations are not evident in all the reported studies. Some
reports did not find such associations [38]. In addition,
other reports indicated the association between FGF23
and adverse events in a general population whose FGF23
level is not so high [38].
The association between FGF23 level and various
adverse events does not necessarily indicate the direct
cause-effect relationship. However, Faul et al. reported
that FGF23 directly acted on cardiomyocytes and
induced LVH independent of Klotho [39, 40]. Therefore,
it was postulated that FGF23 causes cardiovascular dis-
eases by directly acting on the heart. However, there
remain several questions concerning the relationship
between FGF23 level and various adverse events. First,
FGF23 was shown to activate FGFR4 independent of
Klotho [40]. Because the affinity of FGF23 for FGF
receptors is low [12], it is not clear how FGF23 can acti-
vate FGFR4 in cardiomyocytes without Klotho. Second,
if FGF23 affects cardiomyocytes directly and induces
LVH, LVH could be prevented by blocking FGF23
actions. However, the blockade of FGF23 effects by anti-
FGF23 antibody did not reduce the expression of hyper-
trophic marker genes in an animal model of CKD [41].
Third, FGF23 level was also reported to be associated
with various parameters other than cardiovascular dis-
eases such as fractures, progression of CKD, insulin
resistance, high C-reactive protein, and abnormal lipid
profile [38, 42]. However, it is not known whether
FGF23 affects these parameters by directly acting on
several tissues like the bone, kidney, fat, and muscle.
Fourth, it is not clear either whether the association
between FGF23 and cardiovascular events in general
population is explained by direct effects of FGF23 on the
heart. Recent studies suggest that inflammation or oxi-
dative stress can increase FGF23 level [43–46]. Thus, it
is necessary to clarify the regulatory mechanisms and
the determinants of FGF23 levels to further elucidate
the role of FGF23 especially in patients with CKD.
Conclusions
The identification of FGF23 and the subsequent investiga-
tions established that FGF23-Klotho axis plays essentialroles in the regulation of phosphate and vitamin D metab-
olism. However, there still remain many important ques-
tions concerning this pathway. Especially, the detailed
regulatory mechanisms of FGF23 production and activities
need to be clarified. Therefore, it has not yet been estab-
lished whether the suppression of FGF23 activities is
beneficial for patients with CKD. We hope that further
studies elucidate unsolved problems concerning FGF23-
Klotho axis and will be useful for more appropriate man-
agement of patients with CKD.
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